Oral contraceptives and menopausal hormone therapy: Relative and attributable risks of cardiovascular disease, cancer, and other health outcomes

Annals of Epidemiology

Volumn 25, Issue 3, 2015, Pages 193-200

  Bassuk, Shari S ^a   Manson, JoAnn E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Attributable risk; Attributable risk percent; Cancer; Coronary heart disease; Menopausal hormone therapy; Oral contraceptives; Relative risk; Stroke; Venous thromboembolism; Women

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ARTICLE; ATTRIBUTABLE RISK; BRAIN ISCHEMIA; BREAST; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLIMACTERIUM; COLORECTAL CANCER; CONTRACEPTION; CORONARY RISK; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; HEALTH STATUS; HORMONAL THERAPY; HUMAN; LIVER CANCER; MENOPAUSAL HORMONE THERAPY; MENOPAUSE; META ANALYSIS; NEOPLASM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; FEMALE; HORMONE SUBSTITUTION; MIDDLE AGED; RISK; WOMEN'S HEALTH;

AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; RISK; RISK ASSESSMENT; RISK FACTORS; STROKE; WOMEN'S HEALTH;

EID: 84923300067     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2014.11.004     Document Type: Article

References (52)

1. ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010, 115:206-218. American College of Obstetricians and Gynecologists.
2. Mosher W.D., Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23 2010, 1-44.
3. Jones J., Mosher W., Daniels K. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. National Health Statistics Reports; no. 60 2012, National Center for Health Statistics, Hyattsville MD.
4. Hall K.S., Trussell J. Types of combined oral contraceptives used by US women. Contraception 2012, 86:659-665.
5. Stadel B.V. Oral contraceptives and cardiovascular disease (first of two parts). NEngl J Med 1981, 305:612-618.
6. Stadel B.V. Oral contraceptives and cardiovascular disease (second of two parts). NEngl J Med 1981, 305:672-677.
7. Beral V., Doll R., Hermon C., Peto R., Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008, 371:303-314.
8. Kaunitz A.M. Clinical practice. Hormonal contraception in women of older reproductive age. NEngl J Med 2008, 358:1262-1270.
9. Peragallo Urrutia R., Coeytaux R.R., McBroom A.J., Gierisch J.M., Havrilesky L.J., Moorman P.G., et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol 2013, 122:380-389.
10. Chasan-Taber L., Stampfer M.J. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998, 128:467-477.
11. US. medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep 2010, 59:1-86. Centers for Disease Control.
12. Stampfer M.J., Willett W.C., Colditz G.A., Speizer F.E., Hennekens C.H. Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol 1990, 163:285-291.
13. de Bastos M., Stegeman B.H., Rosendaal F.R., Van Hylckama Vlieg A., Helmerhorst F.M., Stijnen T., et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014, CD010813.
14. Chakhtoura Z., Canonico M., Gompel A., Thalabard J.C., Scarabin P.Y., Plu-Bureau G. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke 2009, 40:1059-1062.
15. Chakhtoura Z., Canonico M., Gompel A., Scarabin P.Y., Plu-Bureau G. Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. JClin Endocrinol Metab 2011, 96:1169-1174.
16. Reid R.L., Westhoff C., Mansour D., de Vries C., Verhaeghe J., Boschitsch E., et al. Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009. JFam Plann Reprod Health Care 2010, 36:117-122.
17. Lidegaard O., Nielsen L.H., Skovlund C.W., Skjeldestad F.E., Lokkegaard E. Risk ofvenous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011, 343:d6423.
18. Lidegaard O., Lokkegaard E., Jensen A., Skovlund C.W., Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. NEngl J Med 2012, 366:2257-2266.
19. Hannaford P.C., Selvaraj S., Elliott A.M., Angus V., Iversen L., Lee A.J. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007, 335:651.
20. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996, 347:1713-1727. Collaborative Group on Hormonal Factors in Breast Cancer.
21. Gierisch J.M., Coeytaux R.R., Urrutia R.P., Havrilesky L.J., Moorman P.G., Lowery W.J., et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013, 22:1931-1943.
22. IARC monographs on the evaluation of carcinogenic risks to man. Volume 100A-19, Pharmaceuticals: combined estrogen-progestogen contraceptives 2012, 283-311. International Agency for Research on Cancer, International Agency for Research on Cancer, Lyon.
23. Havrilesky L.J., Moorman P.G., Lowery W.J., Gierisch J.M., Coeytaux R.R., Urrutia R.P., et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol 2013, 122:139-147.
24. Moorman P.G., Havrilesky L.J., Gierisch J.M., Coeytaux R.R., Lowery W.J., Peragallo Urrutia R., et al. Oral contraceptives and risk ofovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. JClin Oncol 2013, 31:4188-4198.
25. Bosetti C., Bravi F., Negri E., La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 2009, 15:489-498.
26. Whitmer B.A., Fields J.M., Piper M.H. Hepatocellular adenoma. Medscape Available at, Accessed June 27, 2014. http://emedicine.medscape.com/article/170205-overview#a0199.
27. Vessey M., Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception 2013, 88:678-683.
28. Isley M.M., Kaunitz A.M. Update on hormonal contraception and bone density. Rev Endocr Metab Disord 2011, 12:93-106.
29. Michaelsson K., Baron J.A., Farahmand B.Y., Persson I., Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet 1999, 353:1481-1484.
30. Barad D., Kooperberg C., Wactawski-Wende J., Liu J., Hendrix S.L., Watts N.B. Prior oral contraception and postmenopausal fracture: a Women's Health Initiative observational cohort study. Fertil Steril 2005, 84:374-383.
31. Hannaford P.C., Iversen L., Macfarlane T.V., Elliott A.M., Angus V., Lee A.J. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010, 340:c927.
32. Colditz G.A. Oral contraceptive use and mortality during 12 years of follow-up: the Nurses' Health Study. Ann Intern Med 1994, 120:821-826.
33. Vessey M., Yeates D., Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception 2010, 82:221-229.
34. Manson J.E., Bassuk S.S. The menopause transition and postmenopausal hormone therapy. Harrison's principles of internal medicine 2011, McGraw-Hill, New York, NY. D.L. Longo, A.S. Fauci, D.L. Kasper, S.L. Hauser, J.L. Jamison, J. Loscalzo (Eds.).
35. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. Writing Group for the Women's Health Initiative Investigators.
36. Santen R.J., Allred D.C., Ardoin S.P., Archer D.F., Boyd N., Braunstein G.D., et al. Postmenopausal hormone therapy: anEndocrine Society scientific statement. JClin Endocrinol Metab 2010, 95:S1-S66.
37. Hersh A.L., Stefanick M.L., Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004, 291:47-53.
38. Sprague B.L., Trentham-Dietz A., Cronin K.A. Asustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012, 120:595-603.
39. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010, 17:242-255. North American Menopause Society.
40. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712. Women's Health Initiative Steering Committee.
41. Manson J.E., Chlebowski R.T., Stefanick M.L., Aragaki A.K., Rossouw J.E., Prentice R.L., et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013, 310:1353-1368.
42. Wassertheil-Smoller S., Hendrix S.L., Limacher M., Heiss G., Kooperberg C., Baird A., et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003, 289:2673-2684.
43. Hendrix S.L., Wassertheil-Smoller S., Johnson K.C., Howard B.V., Kooperberg C., Rossouw J.E., et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006, 113:2425-2434.
44. Chlebowski R.T., Anderson G.L. Changing concepts: menopausal hormone therapy and breast cancer. JNatl Cancer Inst 2012, 104:517-527.
45. Bassuk S.S., Manson J.E. Menopausal hormone therapy and cardiovascular disease risk: utility of biomarkers and clinical factors for risk stratification. Clin Chem 2014, 60:68-77.
46. Mendelsohn M.E., Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 2005, 308:1583-1587.
47. Manson J.E., Bassuk S.S. Invited commentary. Hormone therapy and risk of coronary heart disease: why renew the focus on the early years of menopause?. Am J Epidemiol 2007, 166:511-517.
48. Bray P.F., Larson J.C., Lacroix A.Z., Manson J., Limacher M.C., Rossouw J.E., et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 2008, 101:1599-1605.
49. Wild R.A., Wu C., Curb J.D., Martin L.W., Phillips L., Stefanick M., et al. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause 2013, 20:254-260.
50. Cushman M., Kuller L.H., Prentice R., Rodabough R.J., Psaty B.M., Stafford R.S., et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004, 292:1573-1580.
51. Stefanick M.L., Anderson G.L., Margolis K.L., Hendrix S.L., Rodabough R.J., Paskett E.D., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006, 295:1647-1657.
52. Petitti D.B. Hormonal contraceptives and arterial thrombosis-not risk-free but safe enough. NEngl J Med 2012, 366:2316-2318.